Publications
Detailed Information
Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, D H | - |
dc.contributor.author | Li, K | - |
dc.contributor.author | Suh, D H | - |
dc.date.accessioned | 2010-06-07T05:44:17Z | - |
dc.date.available | 2010-06-07T05:44:17Z | - |
dc.date.issued | 2008-03-28 | - |
dc.identifier.citation | Br J Dermatol. 2008;158(5):1069-76 | en |
dc.identifier.issn | 0007-0963 (Print) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18363758 | - |
dc.identifier.uri | https://hdl.handle.net/10371/67543 | - |
dc.description.abstract | BACKGROUND: Steroid-induced rosacea is a relatively common dermatosis that is caused by the prolonged application of topical steroid to the face. OBJECTIVES: The purpose of this investigator-blind, split-face study was to evaluate the efficacy and safety of pimecrolimus 1% cream for the treatment of steroid-induced rosacea. PATIENTS/METHODS: Patients were instructed to apply pimecrolimus 1% cream twice daily to the involved areas of a randomly allocated half side for the first 2 weeks, and to follow this by applying pimecrolimus 1% cream to both sides for a further 6 weeks. RESULTS: Fifteen of the 18 patients completed the 8-week study. After 1 week of application, a statistically significant improvement was observed for investigator's global assessments of erythema and papules on prior-treated sides (P-side). Later-treated sides (L-side) showed subsequent improvement after use of pimecrolimus on the L-side. Likewise, a statistically significant improvement was also observed for numbers of papules/pustules on P-sides after 1 week, and L-sides showed a significant improvement after application of pimecrolimus on the L-side. Comparative reflectance colorimetric assessments revealed that DeltaL*, Deltaa* and Deltab* tended to converge to zero during the first 4 weeks. A statistically significant improvement was observed for percentage area affected on P-sides after 1 week of application. The L-side showed a significant improvement after use of pimecrolimus cream on that side. The visual analogue scale of P-sides decreased more rapidly than those of L-sides. Cutaneous side-effects were mild and transient. CONCLUSIONS: This study suggests that pimecrolimus 1% cream is an effective and well-tolerated treatment for steroid-induced rosacea. | en |
dc.language.iso | en | en |
dc.publisher | Wiley-Blackwell | en |
dc.subject | Administration, Cutaneous | en |
dc.subject | Adrenal Cortex Hormones/*adverse effects | en |
dc.subject | Dermatologic Agents/*therapeutic use | en |
dc.subject | Humans | en |
dc.subject | Male | en |
dc.subject | Pain Measurement | en |
dc.subject | Rosacea/chemically induced/*drug therapy | en |
dc.subject | Single-Blind Method | en |
dc.subject | Tacrolimus/*analogs & derivatives/therapeutic use | en |
dc.title | Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial | en |
dc.type | Article | en |
dc.identifier.doi | 10.1111/j.1365-2133.2008.08496.x | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.